Trials / Completed
CompletedNCT01235975
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years
Phase IIIb Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Meningococcal Vaccine [GSK 134612] When Given as One Dose to Healthy Subjects Aged 56 Years or Older
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 56 Years
- Healthy volunteers
- Accepted
Summary
This study evaluates the immunogenicity and safety of the meningococcal conjugate vaccine GSK 134612 given as single dose to healthy adults 56 years or older compared to the meningococcal polysaccharide vaccine MencevaxACWYTM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Meningococcal vaccine GSK 134612 | Intramuscular injection |
| BIOLOGICAL | MencevaxACWY TM | Subcutaneous injection |
Timeline
- Start date
- 2010-11-30
- Primary completion
- 2011-07-29
- Completion
- 2011-08-03
- First posted
- 2010-11-08
- Last updated
- 2018-08-20
- Results posted
- 2017-04-28
Locations
1 site across 1 country: Lebanon
Source: ClinicalTrials.gov record NCT01235975. Inclusion in this directory is not an endorsement.